Kode ti kaïngo kobela ti cancer ti prostate ayeke so wa?
Pathophysiologie ti cancer ti prostate andu aye so ayeke na gunda ni nga na aye so ayeke si na pekoni ti sala si kobela ni amaï na ague na li ni.
Kanser ti prostate ayeke mbeni sioni kobela so ayeke maï na yâ ti akete cellule ti prostate, mbeni kete mbage ti tere ti koli so akpa noix so ayeke na gbe ti vésicule ti koli.
Glande ti prostate ayeke sigigi na ngu ti yâ ti koli, so ayeke mû kobe na akoli na ayeke yô ala.
A hinga mbilimbili pëpe ye so ayeke na gunda ti cancer ti prostate, me a hinga ambeni ye so ayeke sara si kobela ni ayeke gue na li ni.
Aye so andu ngu ti zo, sewa ti lo, mara ti lo nga na ambeni ye so ayeke na yâ mênë ti lo.
Azo mingi ayeke wara kobela ti cancer ti prostate na popo ti akoli so ngu ti ala ahon 65.
Na ndo ni, tongana mbeni zo ti sewa ti mo ayeke na cancer ti prostate, kobela ni alingbi ti gbu lo nga.
Kode so a yeke sala na kusala na cancer ti prostate andu guengo na li ni nga na kangbingo yâ ti acellule ti yâ ti prostate so a lingbi ti kanga lege na ni pëpe.
Ye so alingbi ti si na lege ti ambeni ye so a gbian na yâ mênë ti zo, so asala si ambeni ye so ayeke kono na yâ mênë ti zo asigigi mingi ahon ndo ni wala asala si ambeni ye so ayeke kanga lege na maïngo ti kobela ni asigigi pëpe.
Akete ye so alingbi ti sara si acellule ni akono kirikiri na a sara si mbeni cancer abâ gigi.
Tongana cancer ni ayeke kono, lo lingbi ti lï na yâ ti ambeni mbage ti tere ti zo so ayeke nduru na lo, na tapande, yâ ti poche ti ngu, yâ ti ngbonda ti zo nga na yâ ti ambeni lymphe so ayeke nduru na lo.
Na yâ ti ambeni ye, acellule ti cancer alingbi ti sigigi na yâ ti kozo cancer ni na ti mû yâ ti mênë ti gue na ambeni mbage ti tere ti zo.
Tongana cancer ni amû ndo kue awe, a yeke ngangu ti sava ni.
Ambeni ye so ayeke na yâ ti tere ti koli alingbi ti sara nga ngangu na ndo ti kobela ti cancer ti prostate, mbilimbili androgène so ayeke testostérone.
Testostérone alingbi ti pusu acellule ti cancer ti prostate ti kono, na mingi ti ayorö ti kaïngo na cancer ti prostate ayeke gi ti sala si wungo ti hormone so akiri na peko wala ti kanga lege na ni ti sala kusala.
Na ndulu tënë, kobela ti cancer ti prostate andu guengo na li ni nga na kangbingo yâ ti acellule ti prostate so ayeke na gbe ti ngangu ti aye tongana aye tongana acellule ti yâ ti mama, aye tongana yorö ti tere ti zo nga na aye so angoro zo.
Ti hinga ye so ayeke na gunda ti kobela ni ayeke kota ye mingi ti wara anzoni yorö ti kaï na ni nga ti sara si kobela ti cancer ti prostate so ague na zo na kobela ni ahunzi nzoni.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
['Tënë ti ziango kamene na lê: tënë ti seni']
['A zia site so gi ti fa na ye na azo na ti mû wango na ala.']
['A lingbi a sala kusala pëpe na asango so a mû ti hinga wala ti kaï na mbeni kpale ti seni wala kobela, na a lingbi ala so aye ti wara wango ti kaïngo kobela teti ala mveni ahunda mbeni wanganga so ayeke na mbeti ti hinga ye na ndo ni.']
['Bâ so tongana a hunda na zo ti fa wungo ti azo so ayeke na mbeni kobela, a yeke ngangu ti tene lo fa tâ wungo ti azo ni.']
['Gi lakue wango ti wanganga ti mo wala mbeni wanganga so ahinga kua ti lo nzoni na ndo ti kobela ti mo. Zia lâ oko pëpe ti ke wango ti wanganga wala ti ku ti wara ni ndali ti mbeni ye so mo diko na ndo ti site so. Tongana mo bâ so mo yeke na yâ ti mbeni kpale ti seni, iri 911 wala gue hio na hôpital so ayeke nduru na mo.']
['Kengo tene: droit ti lo ti sala tene']
['Ndia ti Amerika na ndo droit ti sigingo na ambeti (Digital Millennium Copyright Act) ti ngu 1998, 17 U.S.C. § 512 (so a hiri ni DMCA) amû lege na azo so ayeke na droit ti sigingo na ambeti ti bâ wala ambeti so asigigi na ndo ti Internet ni adoro droit ti ala so ndia ti Amerika amû na ndo droit ti sigingo na ambeti amû lege na ala ti sala ni. ']
['Tongana mo pensé so mbeni ye so ayeke na ndo ti site ti e wala na yâ ti ambeni ye so e yeke sara andu droit ti mo ti batango ambeti ti e, mo (wala zo so mo sara kua na iri ti lo) alingbi ti tokua na e mbeni mbeti ti hunda ti tene a zi ni wala a kanga lege na mo ti wara ni.']
['A lingbi a tokua ambeti ni na lege ti mbeni lettre so a sû na ndo ti ordinateur wala na lege ti mbeni téléphone (bâ mbage "A-adresse ti téléphone").']
['Ndia ti DMCA ahunda ti tene na yâ ti mbeti ti mo so a tene mbeni zo asara mbeni ye so ake ndia ti droit ti batango ambeti, mo zia atënë so ge: (1) fango peko ti kua so ndia ti batango ambeti ni ake ni; (2) fango peko ti aye so a tene a sara ye ti ke ndia ti batango ambeti ni nga na atënë so alingbi ti mû lege na e ti wara aye ni so; (3) asango ti mo ti wara mo, so andu adresse ti mo, numéro ti téléphone ti mo nga na adresse ti e-mail ti mo; (4) mbeni tënë so mo tene na bê ti mo kue so tënë ti aye ni so mo dema tere dä so ayeke pëpe tënë ti zo so ayeke na droit ti batango ambeti ni, wala zo so ayeke sara kua na iri ti lo, wala ndia ti kodoro ti mo.']
['(5) Mo sû maboko ti mo na gbe ti ngbanga ti mvene na mo tene so atënë so ayeke na yâ ti mbeti ni ayeke tâ tënë nga so mo yeke na ngangu ti sara si a bata droit ti mo ti sigingo na ambeti so a tene a doro ni.']
['Nga (6) mbeni maboko ti zo so ayeke na droit ti sigingo na ambeti ni wala mbeni maboko ti mbeni zo so ayeke sara kua na iri ti zo ni.']
['Tongana mo sû atënë so kue pëpe, a lingbi ti sara si a mû ngoi mingi pëpe ti bâ lege ti tënë ti mo ni.']
['Tënë ti kiri ti bâ zo']
['Tongana mo yeke na mbeni hundango tënë wala mbeni tënë ti tene, tokua ni na e na lege ti mbeni lettre.']
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Na ndo ni']
['Na yâ ti BioMedLib, a yeke sala kusala na a-ordinateur so ayeke sala kua gi na ndo ti tele ti ala mveni (na lege ti kode ti mandango ye na lege ti masini) ti leke ahundango tënë na akiringo tënë so a zia na tele ti mba.']
['E to nda ni na ambeti ti senda-ye kutu 35 so ayeke na yâ ti ambeti-sango so a iri ni PubMed/Medline nga na ambeni site ti e so a iri ni RefinedWeb.']
